Seronegative spondyloarthropathy-associated inflammatory bowel disease

Table 2 Demographic, clinical, laboratory, therapeutic, and prognostic profiles in two main types of inflammatory bowel disease

Category	Ulcerative colitis	Crohn’s disease
Demographic
Sex, M:F	1:1	1:1
Age at onset in yr	30-50	10-40
Laboratory
ANCA	Common	Rare
ASCA	Rare	Common
Clinical
Origin/Location	Rectum/colon, rectum	Terminal ileum/any part
Distribution	Continuous	Skip lesions
Pathology
Inflamed thickness	Mucosa, submucosa	Transmural
Crypt abscess	Common	Uncommon
Granuloma	Rare	Common
Fissure	Uncommon	Common
Fibrosis	Rare	Common
Treatment	ASA, CS, IS, biologics, JAKi, S1PR modulator, surgery for refractory medical disease or malignancy	CS, IS, biologics, surgery for refractory medical disease, complication or malignancy
Prognosis	Complete remission in most patients, low surgical requirement	Prolonged remission in about 20% of patients, 10-yr surgical resection risk near 50%

ANCA: Anti-neutrophil cytoplasmic antibody; ASA: Aminosalicylate; ASCA: Anti-Saccharomyces cerevisiae antibody; CS: Corticosteroid; IS: Immunosuppressant; JAKi: Janus kinase inhibitor; SIPR: Sphingosine-1-phosphate receptor.